Aspirin has been a widely used antiplatelet drug for management of cardiovascular disease for last five decades. Multiple studies have established its role in secondary prevention of cardiovascular diseases. For primary prevention, the situation is not so simple. Initial studies (though large and with long follow up) performed two decades ago suggested an impressive positive risk -benefit profile. But such benefits could not be replicated in subsequent studies performed in the new millennium. Recently, three back to back studies of aspirin in primary prevention in contemporary era failed to demonstrate any benefits or the benefits were counterbalanced by bleeding events. Hence, the role of aspirin for primary prevention of cardiovascular disease is under intense scrutiny.
INTRODUCTION
The fascinating story of "the wonder drug" aspirin dates back >3500 years when willow bark was used as a painkiller and antipyretics by Hippocrates and other people. Bayer marketed it in the 19 th century. Its use as antiplatelet drug started in the late 1960s and early 1970s. [1] Since then, role of low-dose aspirin in cardiovascular (CV) protection has been supported by >200 studies involving >200,000 patients. [2] Aspirin has been well established in the secondary prevention of Cardiovascular diseases (CVDs). However, despite multiple studies, the role of aspirin for the primary prevention remains controversial.
ASPIRIN FOR PRIMARY PREVENTION: THE GOLDEN PHASE
Six large randomized studies have tested the role of aspirin for the primary prevention of CVDs since the late 1980s [ Table 1 ]. The largest two among them are worth mentioning. In 1989, The Physicians' Health Study randomized 22,071 male participants to aspirin, with an average follow-up of 60 months. Aspirin use was associated with a 44% reduction in the risk of myocardial infarction (MI); however, this effect was mainly present in men >50 years of age and no reduction in total CV mortality (risk ratio: 0.96; 95% confidence interval: 0.60-1.54) was observed. A slightly increased risk of stroke was observed among those taking aspirin.
[3] The Women's Health Study randomized 39,876 healthy women aged >45 years of age to low-dose aspirin (100 mg every other day) versus placebo for a mean follow-up of 10 years. They found no reduction in the primary composite end-point of nonfatal MI, nonfatal stroke, or death from a CV cause. Aspirin use, however, was associated with a 17% reduction in the risk of stroke. [4] The pivotal Antithrombotic Trialists Collaboration meta-analysis pooled individual patient data of 95,000 patients from these six primary prevention studies. [2] The collaborative meta-analysis demonstrated 12% reduction in serious vascular events with the use of aspirin which was driven principally by 23% reduction in nonfatal MI [ Figure 1 ]. [2] There was also a 14% reduction in ischemic strokes which was counterbalanced by increase in hemorrhagic strokes by 32%. The net effect on strokes was not significant, while the effect on vascular mortality was not different from placebo. These benefits were accrued at the cost of almost 50% increase in bleeding which were chiefly gastrointestinal (GI) and extracranial in location.
DIFFERENTIAL EFFECT OF ASPIRIN BASED ON GENDER -MEN ARE FROM VENUS AND WOMEN ARE FROM MARS!
Interestingly, despite the varied sex-specific inclusion criteria in majority of these studies, the benefits of aspirin in the above-mentioned meta-analysis were independent of gender and baseline 5-year CV risk. One sex-specific meta-analysis of six large studies studied 51,342 women and 44,114 men randomized to aspirin (doses ranging between 100 mg every other day and 500 mg daily) versus placebo for 3.7 years-10 years. Aspirin therapy was associated with a significant 12% reduction in CV events and a 17% reduction in stroke, predominantly resulting from reduced rates of ischemic stroke in females, but there was no significant effect on MI or CV mortality. While in males, aspirin therapy was associated with a significant 14% reduction in CV events and a 32% reduction in MI. There was no significant effect on stroke or CV mortality. [5] Hence, these initial trials and meta-analyses demonstrated clear efficacy of aspirin. Based on these studies, low-dose aspirin was given Class IIa recommendation for females >65 years of age at risk for primary prevention and Class IIb recommendation for females <65 years of age for ischemic stroke prevention. [6] Aspirin (75-162 mg daily) in men at intermediate risk (10-year risk of coronary heart disease >10%) was advised for primary prevention. [7] The American College of Cardiology along with the American Heart Association also gave Class IIa recommendation to low-dose aspirin in 2010 in adults with diabetes mellitus (DM) and no previous history of vascular disease who are at increased CVD risk (10-year risk >10%) and who are not at increased risk for bleeding. Those adults with DM at increased CVD risk include most men >50 years of age or women >60 years of age who have at least one additional major risk factor. [8] FALLOUT OF ASPIRIN IN THE NEW MILLENIUM After 2008, many negative studies came into the picture. Two studies (POPADAD and JPAD studies) assessed effects of aspirin in diabetes. Aspirin was not found to reduce the risk of adverse CV events in diabetic patients in these studies. [9, 10] Subsequently, aspirin was not found to reduce the risk of CV events in those with an Ankle-Brachial Index <0.95 in The Aspirin for Asymptomatic Atherosclerosis trial. [11] There was a 14% reduction in ischemic strokes too, but the net effect on stroke was nonsignificant.
Vascular mortality also did not differ between the groups. (MI: Myocardial infarction)
However, the updated systematic review of 11 randomized controlled trials (incorporating the above trials), published by the US Preventive Services Task Force in 2016, still revealed an impressive 22% relative risk reduction in nonfatal MI with aspirin but only minor reduction in nonfatal stroke, CV death, and total mortality [ Figure 2] . [12] Interestingly, elderly patients demonstrated more robust reduction in MI. At lower doses of aspirin (<100 mg), 14% reduction in nonfatal strokes were seen, while reduction on MI was sustained. However, aspirin use increased major GI bleeding risk by 58% and hemorrhagic stroke risk by 27%. [13, 14] Such conflicting results with aspirin studies have led to inconsistent guidelines for aspirin use in primary prevention. Some societies were in favor of aspirin use, while others were against its use. The US. Preventive Services Task Force recommends low-dose aspirin use for the primary prevention of CVD in adults aged 50-59 years who have a 10% or greater 10-year CVD risk [ Figure 3 ]. While in adults aged 60-69 years who have a 10% or greater 10-year CVD risk, aspirin initiation was advised on individual basis. [15] Use of aspirin for the primary prevention of CVD was not endorsed by European Guidelines due to lack of clear evidence in support of its efficacy and increase in bleeding events. [16] 
2018: WATERLOO FOR ASPIRIN
In the background of emerging equivocal data about the role of aspirin primary prevention, three large randomized trials involving close to 47,000 patients were published recently.
These three trials tried to address the unresolved issues of aspirin in primary prevention to some extent [ Table 2 ]. In the ASCEND trial, aspirin use was tested in 15,840 persons with diabetes but without overt CVD. [17] At a median follow-up of 7.4 years, aspirin prevented serious CV events by 12%, but it also caused a 29% rise in major bleeding events. Hence, bleeding events counterbalanced the absolute benefits seen with aspirin use for primary prevention. The ARRIVE trial enrolled 12,546 patients (age >55 years for men and >60 for women) with moderate CV risk across seven countries. The use of aspirin did not decrease the risk of major CV events in the patients vis-a-vis placebo (hazard ratio -0.96; P = 0.6). [18] Again, as in ASCEND study, the GI bleeds were up by two times with the use of drug. ASPREE trial specifically tested aspirin use in 19,114 elderly patients for primary prevention. [19] Treatment with 100 mg/day of aspirin did not decrease major adverse CV events at median follow-up of 4.7 years. In this trial, use of enteric-coated aspirin led to increased major bleeding by 38%. Interestingly, there was increase in death from any cause with aspirin use, especially cancer-related deaths. This is surprising given the established role of aspirin in cancer prevention. [20] These three studies used contemporary pharmacotherapy in the management of CVD. With large sample size and close to half-decade follow-up in these studies, the results would be hard to neglect. One can only speculate about the various possible reasons for contrasting results seen in the pristine trials. The initial aspirin trials occurred in an era when other risk factors of vascular diseases were not well controlled such as blood pressure and lipid profile. With development of statins, renin-angiotensin-aldosterone system blockers, and better management of CV risk factors, event rates are already on decline. Not surprisingly, the statin use was high in these three studies with maximum use in ASCEND study (75%). Variation in sample size, patient population, drug dosage, compliance, event rates, and study design are other possible explanations. Theoretical addition of other preventive strategies such as statin and angiotensin-converting enzyme inhibitors coupled with better control of CV risk factors has the potential to negate the beneficial effects of aspirin in older trials. [21] CONCLUSION The use of aspirin for primary prevention of CVD is now under scrutiny in view of recent trials. Even in diabetic patients, the use of aspirin is controversial in the light of increased bleeding events seen in recent trials. Pending a clear-cut advice from guidelines, routine use of aspirin for primary prevention in all is not advisable at present. Physicians need to take an individualized decision on a case-to-case base. The eternal dilemma still remains the same -balancing the bleeding risk with ischemic benefits.
